Asterias Biotherapeutics (AST) Misses Q1 EPS by 13c

Asterias Biotherapeutics (NYSE: AST) reported Q1 EPS of ($0.27), $0.13 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $870 thousand.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30